Advanced Therapy Medicinal Products (ATMPs) Consulting Market Report 2027

1. Research Methodology
1.1. Secondary Research
1.2. Primary Research
1.3. Market Estimation
1.4. Market Forecasting

2. Executive Summary

3. Market Overview
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunities
3.2. Industry Speaks

4. Advanced Therapy Medicinal Products (ATMPs) Consulting Market - Size & Forecast (2019-2027), By Phase
4.1. Early Stage Development
4.2. Clinical Development
4.3. Commercialization

5. Advanced Therapy Medicinal Products (ATMPs) Consulting Market - Size & Forecast (2019-2027), By Type
5.1. Gene therapy medicinal products
5.2. Somatic cell medicinal products
5.3. Tissue-engineered medicinal products

6. Advanced Therapy Medicinal Products (ATMPs) Consulting Market - Size & Forecast (2019-2027), By Region
6.1. North America (U.S. & Canada)
6.2. Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
6.3. Asia Pacific (China, India, Japan, Rest of Asia Pacific)
6.4. Rest of the World (Latin America, Middle East & Africa)

7. Competitive Landscape
7.1. Key Players and their Competitive Positioning
7.1.1. Competitive Positioning of Key Players (2022)
7.1.2. Service Offerings Assessment, By Players
7.2. Key Strategies Assessment, By Player (2021-2023)
7.2.1. New Service Launches
7.2.2. Partnerships, Agreements, & Collaborations
7.2.3. Mergers & Acquisitions
7.2.4. Other Developments

8. Key Companies Scanned (Indicative List)
8.1. Dark Horse Consulting
8.2. PharmaLex (Acquired by AmerisourceBergen)
8.3. ProPharma Group
8.4. Clarkston Consulting
8.5. Alacrita Life Science Consulting
8.6. Kinesys Consulting
8.7. Voisin Consulting Life Sciences (VCLS)
8.8. QbD Group (Michor Consulting/EUDRAC)
8.9. Advanced Cell & Gene Therapy
8.10. Validant/DataRevive
8.11. Asphalion
8.12. Putnam
8.13. Other Players